EyePoint Pharmaceuticals (EYPT) Competitors $9.17 -1.32 (-12.58%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EYPT vs. FLDM, TRNS, CTKB, LAB, QTRX, AEHR, NAUT, SENS, AKYA, and SEERShould you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include Fluidigm (FLDM), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Quanterix (QTRX), Aehr Test Systems (AEHR), Nautilus Biotechnology (NAUT), Senseonics (SENS), Akoya Biosciences (AKYA), and Seer (SEER). EyePoint Pharmaceuticals vs. Fluidigm Transcat Cytek Biosciences Standard BioTools Quanterix Aehr Test Systems Nautilus Biotechnology Senseonics Akoya Biosciences Seer EyePoint Pharmaceuticals (NASDAQ:EYPT) and Fluidigm (NASDAQ:FLDM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Do analysts rate EYPT or FLDM? EyePoint Pharmaceuticals currently has a consensus target price of $28.00, indicating a potential upside of 205.34%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe EyePoint Pharmaceuticals is more favorable than Fluidigm.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EyePoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Fluidigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, EYPT or FLDM? Fluidigm has higher revenue and earnings than EyePoint Pharmaceuticals. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Fluidigm, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyePoint Pharmaceuticals$46.02M10.66-$70.79M-$2.00-4.59Fluidigm$130.58M0.00-$59.24M-$0.78N/A Is EYPT or FLDM more profitable? Fluidigm has a net margin of -45.36% compared to EyePoint Pharmaceuticals' net margin of -226.57%. Fluidigm's return on equity of -40.15% beat EyePoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets EyePoint Pharmaceuticals-226.57% -43.01% -31.63% Fluidigm -45.36%-40.15%-14.86% Which has more volatility & risk, EYPT or FLDM? EyePoint Pharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Fluidigm has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Does the media favor EYPT or FLDM? In the previous week, EyePoint Pharmaceuticals had 14 more articles in the media than Fluidigm. MarketBeat recorded 14 mentions for EyePoint Pharmaceuticals and 0 mentions for Fluidigm. Fluidigm's average media sentiment score of 0.28 beat EyePoint Pharmaceuticals' score of 0.07 indicating that Fluidigm is being referred to more favorably in the news media. Company Overall Sentiment EyePoint Pharmaceuticals Neutral Fluidigm Neutral Do institutionals and insiders believe in EYPT or FLDM? 99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. Comparatively, 76.6% of Fluidigm shares are held by institutional investors. 4.7% of EyePoint Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Fluidigm shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor EYPT or FLDM? Fluidigm received 53 more outperform votes than EyePoint Pharmaceuticals when rated by MarketBeat users. However, 70.15% of users gave EyePoint Pharmaceuticals an outperform vote while only 63.86% of users gave Fluidigm an outperform vote. CompanyUnderperformOutperformEyePoint PharmaceuticalsOutperform Votes46370.15% Underperform Votes19729.85% FluidigmOutperform Votes51663.86% Underperform Votes29236.14% SummaryEyePoint Pharmaceuticals beats Fluidigm on 9 of the 17 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYPT vs. The Competition Export to ExcelMetricEyePoint PharmaceuticalsAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$490.78M$5.09B$5.06B$8.67BDividend YieldN/A0.43%5.06%4.06%P/E Ratio-4.5923.8998.3417.05Price / Sales10.664.251,206.2071.10Price / CashN/A44.9840.6936.36Price / Book2.242.166.325.87Net Income-$70.79M$515,312.50$119.47M$225.66M7 Day Performance-21.15%-11.04%-5.11%-1.34%1 Month Performance-18.71%-9.48%-3.20%1.00%1 Year Performance48.38%-16.15%32.42%25.27% EyePoint Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYPTEyePoint Pharmaceuticals2.8493 of 5 stars$9.17-12.6%$28.00+205.3%+48.4%$625.86M$45.71M-4.59120Short Interest ↑Analyst RevisionFLDMFluidigmN/AN/AN/AN/A$283.76M$130.58M-4.76615Analyst ForecastTRNSTranscat3.2559 of 5 stars$110.13+3.5%N/A+14.3%$1.01B$259.48M55.621,104Positive NewsCTKBCytek Biosciences3.3399 of 5 stars$7.05-2.4%N/A+1.4%$927.15M$193.01M-88.11500Short Interest ↓Gap DownLABStandard BioTools3.4364 of 5 stars$2.15-1.4%N/A-28.2%$797.97M$106.34M-3.03620Positive NewsQTRXQuanterix3.1641 of 5 stars$15.10+0.1%N/A-47.8%$579.54M$122.37M-14.38460Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsAEHRAehr Test Systems2.3869 of 5 stars$12.00-0.2%N/A-57.6%$355.56M$66.22M12.2590Short Interest ↑NAUTNautilus Biotechnology2.1634 of 5 stars$2.49-6.4%N/A-22.0%$312.64MN/A-4.45130Positive NewsHigh Trading VolumeSENSSenseonics1.6231 of 5 stars$0.31-12.5%N/A-52.6%$165.23M$24.04M-2.3790Analyst ForecastHigh Trading VolumeAKYAAkoya Biosciences1.9915 of 5 stars$3.17-1.6%N/A-47.3%$156.92M$96.63M-2.5890Analyst ForecastShort Interest ↓News CoverageGap DownSEERSeer2.3576 of 5 stars$2.38+7.2%N/A+57.1%$146.20M$16.66M-1.83160Short Interest ↑ Related Companies and Tools Related Companies FLDM Alternatives TRNS Alternatives CTKB Alternatives LAB Alternatives QTRX Alternatives AEHR Alternatives NAUT Alternatives SENS Alternatives AKYA Alternatives SEER Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EYPT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYPT Stock Alerts